Medical devices and technology companies continue their strong performance of late as investors look ahead to the future of healthcare. We have recently talked about a number of compelling investments in this space, such as Immunogen (IMGN) and Steris Corp (STE). The following article continues the trend and looks at the fast growing company Endologix (ELGX) with an advanced patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). With over 200,000 people diagnosed in the US each year, ELGX continues to gain market share and has impressive upside capabilities over the medium term offering over 40% upside at current levels.
While 200,000 people are diagnosed each year in the US, it...
Only subscribers can access this article, which is part of the PRO research library covering 3,608 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: